Clinical Trial Update: IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial [Phase 2]

View source ↗

Summary

Phase 2 trial update noting that IN10018 combined with nab-paclitaxel and cadonilimab for metastatic or recurrent gastric-type cervical adenocarcinoma is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Adenocarcinoma
• Gastric-type Endocervical Adenocarcinoma

Drugs mentioned

• Cadonilimab
• IN10018
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Cervical Adenocarcinoma, Gastric-type Endocervical Adenocarcinoma | Phase 2 | Status: RECRUITING